Oxaliplatin induced-neuropathy in digestive tumors

Critical Reviews in Oncology/Hematology

Volumn 89, Issue 1, 2014, Pages 166-178

  Sereno, María ^a   Gutiérrez Gutiérrez, Gerardo ^a   Gómez Raposo, César ^a   López Gómez, Miriam ^a   Merino Salvador, Maria ^a   Tébar, Francisco Zambrana ^a   Rodriguez Antona, Cristina ^b   Casado, Enrique ^a  

^a HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^b National Center in Oncology Research   (Spain)

Author keywords

Digestive tumors; Oxaliplatin; Peripheral neuropathy

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM MAGNESIUM); ALPHA TOCOPHEROL; AMIFOSTINE; CARBAMAZEPINE; CELECOXIB; CYANOCOBALAMIN; DULOXETINE; GABAPENTIN; GINKGO BILOBA EXTRACT; GLUTATHIONE; KAMPO; LEVACECARNINE; OXALIPLATIN; OXCARBAZEPINE; PREGABALIN; THIOCTIC ACID; VENLAFAXINE; XALIPRODEN;

COLON CANCER; COLORECTAL CANCER; DEPRESSION; DIABETIC NEUROPATHY; DIGESTIVE SYSTEM TUMOR; EPILEPSY; HUMAN; NEUROLOGIC EXAMINATION; NEUROMODULATION; NEUROPATHY; NEUROPROTECTION; NEUROTOXICITY; PARESTHESIA; PATHOGENESIS; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RISK FACTOR;

DIGESTIVE TUMORS; OXALIPLATIN; PERIPHERAL NEUROPATHY;

ANIMALS; ANTINEOPLASTIC AGENTS; DIGESTIVE SYSTEM NEOPLASMS; HUMANS; INCIDENCE; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; RISK FACTORS;

EID: 84890888037     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.08.009     Document Type: Review

References (93)

1. Bécouarn Y., Agostini C., Trufflandier N., Boulanger V. Oxaliplatin: available data in non-colorectal gastrointestinal malignancies. Crit Rev Oncol Hematol 2001, 40:265-272.
2. Hartmann J.T., Lipp H.P. Toxicity of platinum compounds. Expert Opin Pharmacother 2003, 4:889-901.
3. Pasetto L.M., D'Andrea M.R., Rossi E., Monfardini S. Oxaliplatin-related neurotoxicity: how and whyα. Crit Rev Oncol Hematol 2006, 59:159-168.
4. Markman M. Toxicities of the platinum antineoplastic agents. Expert Opin Drug Safe 2003, 2:597-607.
5. Grolleau F., Gamelin L., Boisdron-Celle M. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001, 85:2293-2297.
6. de Gramont A., Figer A., Seymour M. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938-2947.
7. Grothey A., Deschler B., Kroening H., et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA+oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002, 21:129a.
8. Brienza S., Vignoud J., Itzhaki M., et al. Oxaliplatin: global safety in 682 patients [abstract]. Proc Am Soc Clin Oncol 1995, 14:209.
9. Taieb S., Trillet-Lenoir V., Rambaud L. Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer 2002, 94:2434-2440.
10. Park S.B., Lin C.S., Krishnan A.V., Goldstein D., Friedlander M.L., Kiernan M.C. Oxaliplatin-induced lhermitte's phenomenon as a manifestation of severe generalized neurotoxicity. Oncology 2009, 77:342-348.
11. Gramont A., Figer A., Seymour M., Homerin M., Hmissi H., Cassidy J. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938-2947.
12. Allegra C.J., Yothers G., O'Connell M.J. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009, 20:3385-3390.
13. Andre T., Boni C., Mounedji-Boudiaf L. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. New Eng J Med 2004, 23:2343-2351.
14. Land J., Kopec J.A., Cecchini R.S. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 2007, 16:2205-2211.
15. Kemeny N., Garay C.A., Gurtler J., et al. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol 2004, 22:4753-4761.
16. Maindrault-Goebel F., Louvet C., Andre T., Carola E., Lotz P., Molitor J.L. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6), GERCOR. Eur J Cancer 1999, 35:1338-1342.
17. Maindrault-Goebel F., Gramont A., Louvet C., Andre T., Carola M., Mabro M. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 2001, 37:1000-1005.
18. Gamelin E., Gamelin L., Bossi L., Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 2002, 29:21-33.
19. Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer 2005, 5(Suppl 1):S38-S46. Review.
20. Ramanathan R.K., Rothenberg M.L., de Gramont A. Incidence and evolution of oxaliplatin induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies. Ann Oncol 2009, 21:754-758.
21. Uwah A.N., Ackler J., Leighton J.C., Pomerantz S., Tester W. The effect of diabetes on oxaliplatin-induced peripheral neuropathy. Clin Colorectal Cancer 2012, 11:275-279.
22. Goldberg R.M., Tabah-Fish I., Bleiberg H. Pooled analysis of safety and efficacy of oxaliplatin plus fluoracil/leucovorin administered bimonthly in ederly patients with colorectal cancer. J Clin Oncol 2006, 24:4085-4091.
23. Argyriou A.A., Briani C., Cavaletti G., et al. Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study. Eur J Neurol 2012, 17:25-36.
24. Vincenzi B., Frezza A.M., Schiavon G., et al. Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Support Care Cancer 2012, 30:125-128.
25. Alejandro L.M., Behrendt C.E., Chen K., Openshaw H., Shibata S. Predicting acute and persistent neuropathy associated with oxaliplatin. Am J Clin Oncol 2012, 27:63-72.
26. Gornet, Savier E.F., Lokiec F., Cvitkovic E., Misset J.L., Goldwasser F. Exacerbation of oxaliplatin neurosensory toxicity following surgery. Ann Oncol 2002, 9:1315-1318.
27. Leonard G.D., Wagner M.R., Quinn M.G., Grem J.L. Severe disabling sensory-motor polyneuropathy during oxaliplatin-based chemotherapy. Anticancer Drugs 2004, 15:733-735.
28. Koskinen M.J., Kautio A.L., Haanpää M.L., et al. Intraepidermal nerve fibre density in cancer patients receiving adjuvant chemotherapy. Anticancer Res 2011, 31:4413-4416.
29. Lecomte T., Landi B., Beaune P., Laurent-Puig P., Loriot M.A. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 2006, 10:3050-3056.
30. Antonacopoulou G.A., Argyriou A.A., Scopa C.D. Integrin beta-3 L33P: a new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathyα. Eur J Neurol 2010, 7:963-968.
31. Argyriou A.A., Velasco R., Briani C., et al. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. Ann Oncol 2012, 2:1965-1974.
32. Sittl R., Lampert A., Huth T., et al. Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype NaV1.6-resurgent and persistent current. PNAS 2012, 20:109-115.
33. Dimitrov A.G., Dimitrova N.A. A possible link of oxaliplatin-induced neuropathy with potassium channel deficit. Muscle Nerve 2012, 45:403-411.
34. Zhao M., Isami K., Nakamura S., Shirakawa H., Nakagawa T., Kaneko S. Acute cold hypersensitivity characteristically induced by oxaliplatin is caused by the enhanced responsiveness of TRPA1 in mice. Mol Pain 2012, 28:55.
35. Ta L.E., Espeset L., Podratz J., Windebank A.J. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 2006, 27:992-1002.
36. Schellingerhout D., LeRoux L.G., Hobbs B.P., Bredow S. Impairment of retrograde neuronal transport in oxaliplatin-induced neuropathy demonstrated by molecular imaging. PLoS One 2012, 7:e45776.
37. Argyriou A.A., Cavaletti G., Briani C., et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer 2013, 119:438-444.
38. Pasetto L.M., D'Andrea M.R., Rossi E., Monfardin S. Oxaliplatin-related neurotoxicity: how and whyα. Crit Rev Oncol Hematol 2006, 59:159-168.
39. Graham G.F., Lockwood D., Greenslade S., Brienza M., Bayssas E. Gamelin clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 2000, 6:1205-1218.
40. Lehky T.J., Leonard G.D., Wilson R.H., Grem J.L. Floeter oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004, 29:387-392.
41. Briani C., Campagnolo M., Lucchetta M., et al. Ultrasound assessment of oxaliplatin-induced neuropathy and correlations with neurophysiologic findings. Eur J Neurol 2013, 20:188-192.
42. Postma T.J., Heimans J.J., Muller M.J. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 1998, 9:739-744.
43. Frigeni B., Piatti M., Lanzani F., et al. Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale. J Peripher Nerv Syst 2011, 16:228-236.
44. Cavaletti G., Bogliun G., Marzorati L., et al. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology 2003, 61:1297-1300.
45. Cornblath D.R., Chaudhry V., Carter K., et al. Total neuropathy score: validation and reliability study. Neurology 1999, 53:1660-1664.
46. Postma T.J., Aaronson N.K., Heimans J.J. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 2005, 41:1135-1139.
47. Cavaletti G., Cornblath D.R., Merkies I.S., et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 2013, 24:454-462.
48. Cassidy J., Misset J.-L. Oxaliplatin-related side effects: characteristics and management. Semin Oncol 2002, 29:11-20.
49. Park S.B., Lin C.S., Krishnan A.V., Goldstein D., Friedlander M.L., Kiernan M.C. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 2009, 132:2712-2723.
50. Gutiérrez-Gutiérrez G., Sereno M., Miralles A., Casado-Sáenz E., Gutiérrez-Rivas E. Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies. Clin Transl Oncol 2010, 12:81-91.
51. Park S.B., Lin C.S., Krishnan A.V., et al. Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist 2011, 16:708-716.
52. American Association of Electrodiagnostic Medicine Technology literature review: quantitative sensory testing. Muscle Nerve 2004, 29:734-747.
53. Cassidy J., Clarke S., Díaz-Rubio E., et al. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer 2011, 105:58-64.
54. Land S.R., Kopec J.A., Cecchini R.S., et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 2007, 25:2205-2211.
55. Argyriou A.A., Polychronopoulos P., Iconomou G., et al. Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. Acta Oncol 2007, 46:1131-1137.
56. Kim H.J., Eun J.Y., Jeon Y.W., et al. Efficacy and safety of oxaliplatin, 5-fluorouracil, and folinic acid combination chemotherapy as first-line treatment in metastatic or recurrent gastric cancer. Cancer Res Treat 2011, 43:154.
57. Yang T., Shen X., Tang X., et al. Phase II trial of oxaliplatin plus oral capecitabine as first-line chemotherapy for patients with advanced gastric cancer. Tumori 2011, 97:466-467.
58. Wainberg Z.A., Lin L.S., DiCarlo B., et al. Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. Br J Cancer 2011, 105:760-765.
59. Li J., Merl M., Lee M.X., Kaley K., Saif M.W. Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience. Expert Opin Drug Safe 2010, 9:207-213.
60. Afchain P., Chibaudel B., Lledo G., et al. First-line simplified GEMOX (S-GemOx) vs classical GEMOX in metastatic pancreatic cancer (MPA): results of a GERCOR randomized phase II study. Bull Cancer 2009, 96:18-22.
61. Overman M.J., Varadhachary G.R., Kopetz S., et al. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol 2009, 27:2598-2603.
62. de Gramont A., Cervantes A., Andre T. OPTIMOX study: FOLFOX7/LV5FU2 compared to FOLFOX4 in patients with advanced colorectal cancer. J Clin Oncol 2004, 22:3525.
63. Argyriou A.A., Chroni E., Polychronopoulos P. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology 2006, 67:2253-2255.
64. Mamiya N., Kono T., Mamiya K. A case of neurotoxicity reduced with goshajinkigan in modified FOLFOX6 chemotherapy for advanced colon cancer. Gan To Kagaku Ryoho 2007, 34:1295-1297.
65. Traa B.S., Mulholland J.D., Kadam S.D. Gabapentin neuroprotection and seizure suppression in immature mouse brain ischemia. Pediatr Res 2008, 64:81-85.
66. Yang Y.H., Lin J.K., Chen W.S., et al. Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study. Support Care Cancer 2012, 20:1491-1497.
67. Xu W.R., Hua B.J., Hou W., Bao Y.J. Clinical randomized controlled study on acupuncture for treatment of peripheral neuropathy induced by chemotherapeutic drugs. Zhongguo Zhen Jiu 2010, 30:457-460.
68. Lu W., Rosenthal D.S. Acupuncture for cancer pain and related symptoms. Curr Pain Headache Rep 2013, 17:321.
69. Yoon J., Jeon J.H., Lee Y.W., et al. Sweet bee venom pharmacopuncture for chemotherapy-induced peripheral neuropathy. J Acupunct Meridian Stud 2012, 5:156-165.
70. Schroeder S., Meyer-Hamme G., Epplée S. Acupuncture for chemotherapy-induced peripheral neuropathy (CIPN): a pilot study using neurography. Acupunct Med 2012, 30:4-7.
71. Velasco R., Petit J., Clapés V., Verdú E., Navarro X., Bruna J. Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients. J Peripher Nerv Syst 2010, 15:17-25.
72. Armstrong C.M., Cota G. Calcium block of Na+ channels and its effect on closing rate. Proc Natl Acad Sci U S A 1999, 96:4154-4157.
73. Gamelin L., Boisdron-Celle M., Delva R., et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004, 10:4055-4061.
74. Saif M.W. Oral calcium ameliorating oxaliplatin-induced peripheral neuropathy. J Appl Res 2004, 4:576-582.
75. Charles L.L., Rui Q., Shaker R.D., et al. Phase III randomized, placebo (PL)-controlled, double-blind study of intravenous calcium/magnesium (CaMg) to prevent oxaliplatin-induced sensory neurotoxicity (sNT), N08CB: An alliance for clinical trials in oncology study. J Clin Oncol 2013, 31(suppl; abstr 3501).
76. Durand J.P., Deplanque G., Montheil V., et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol 2012, 23:200-205.
77. Holmes J., Stanko J., Varchenko M., et al. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol Sci 1998, 46:342-351.
78. Cascinu S., Catalano V., Cordella L., et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2002, 20:3478-3483.
79. Mariani G., Garrone O., Granetto C., et al. Oxaliplatin induced neuropathy: could gabapentin be the answerα. Proc Am Soc Clin Oncol 2000, 19:609.
80. Macdonald R.L., Kelly K.M. Antiepileptic drug mechanisms of action. Epilepsia 1995, 36:S2-S12.
81. Eckel F., Schmelz R., Adelsberger H., Erdmann J., Quasthoff S., Lersch C. Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study. Dtsch Med Wochenschr 2002, 127:78-82.
82. Penz M., Kornek G.V., Raderer M., Ulrich-Pur H., Fiebiger W., Scheithauer W. Subcutaneous administration of amfostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. Ann Oncol 2001, 12:421-422.
83. Argyriou A.A., Kalofonos H.P. Vitamin E for preventing chemotherapy-induced peripheral neuropathy. Support Care Cncer 2011, 19:725-726.
84. Albers J.W., Chaudhry V., Cavaletti G., Donehower R.C. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 2011, 2:CD005228.
85. Daikhin Y., Yudkoff M. Compartmentation of brain glutamate metabolism in neurons and glia. J Nutr 2000, 130:1026S-1031S.
86. Wang W.S., Lin J.K., Lin T.C., et al. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist 2007, 12:312-319.
87. Leonetti C., Biroccio A., Gabellini C. Alpha-tocopherol protects against cisplatin-induced toxicity without interfering with antitumor efficacy. Int J Cancer 2003, 104:243-250.
88. Marshall J., Zakari A., Hwang J., Ginkgo Biloba (GB) extract as a neuroprotective agent in oxaliplatin (Ox)-induced neuropathy. J Clin Oncol 2004, 22:3670.
89. Agafitei R.D., Schneider S., Iqbal S., Rupier W. Effect of celecoxib on neurotoxicity in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin (CIFOX). J Clin Oncol 2004, 22:36-44.
90. Ghirardi O., Lo Giudice P., Pisano C., Ramiro T., Goldman T. Acetyl-l-carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties. Anticancer Res 2004, 25:2681-2687.
91. Cassidy J., Bjarnason G., Hickish T., Wilson H., Gerold Randomized double blind placebo controlled phase III study assessing the efficacy of xaliproden in reducing the cumulative peripheral sensory neuropathy induced by the oxaliplatin and 5FU/LV combination in first line treatment of patients with metastatic colorectal cancer. J Clin Oncol 2006, 24:3507.
92. Grothey A., McLeod H.L., Green E.M., Yu O., Renzo L., Simon T. Glutathione S-transferase P1 I105V (GSTP1 I105V) polymorphism is associated with early onset of oxaliplatin-induced neurotoxicity [abstract]. J Clin Oncol 2005, 23:3509.
93. Sereno M.M., Gutiérrez-Gutiérrez G., Leandro-García L.J., et al. Genetic polymorphisms of scna9 predict oxaliplatin-induced neuropathy. Abstract 94743 ASCO proceedings 2012.